We are live on ! Find out more
XTLB

XTL Biopharmaceuticals
XTLB

4 hedge funds and large institutions have $1.23M invested in XTL Biopharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 4 → 4 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

34% less capital invested

Capital invested by funds: $1.85M → $1.23M (-$627K)

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$20.4K
2
TRCT
Tower Research Capital (TRC)
New York
+$898

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$92.1K
2
UBS Group
UBS Group
Switzerland
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$1.07M -$92.1K -3,588 -6%
Invesco
2
Invesco
Georgia
$134K – – –
Citadel Advisors
3
Citadel Advisors
Florida
$17K +$20.4K +793 New
TRCT
4
Tower Research Capital (TRC)
New York
$1K +$898 +35 +700%
UBS Group
5
UBS Group
Switzerland
– -$1K -18 Closed

XTLB Hedge Fund Activity: Q1 2016 in Review

4 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q1 2016, worth a combined $1.23M — down 34% from $1.85M a quarter earlier.

Fund positioning in XTLB was balanced in Q1 2016: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 1 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $20.4K. The largest seller was Sabby Management, cutting an estimated $92.1K.

  • 4 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q1 2016, unchanged from Q4 2015.
  • Funds reported $1.23M of XTL Biopharmaceuticals stock for Q1 2016, down 34% quarter-over-quarter.
  • 1 fund opened new XTL Biopharmaceuticals positions in Q1 2016 and 1 closed out, a net change of 0 holders.
  • The largest XTL Biopharmaceuticals buyer in Q1 2016 was Citadel Advisors, an estimated $20.4K added.
  • The largest XTL Biopharmaceuticals seller in Q1 2016 was Sabby Management, an estimated $92.1K sold.

Based on aggregated 13F filings for Q1 2016.